Sheng Yin, Ph.D.

Dr. Yin is Chief Technology Officer, and General Manager in China at D2M. As the CTO, he has over 15 years of experience in CMC and IND enabling study & development. In the past, he has successfully delivered multiple IND applications and PD technology transfers, including establishment of the first 10,000 L antibody stainless-steel tank production in China.

Prior to joining D2M, he served as Deputy General Manager at Hengrui-Suzhou Suncadia Biopharmaceuticals, overseeing early- stage process development and late-stage tech transfer and scale-up. Before Hengrui, Dr. Yin held a progressive role in CMC, process development, and analytical science at several biopharma companies including Genetech/Wuxi Biologics/BI (China) and I-mab.

Dr. Yin holds a Ph.D. in Biochemistry and Molecular Biology and a B.S. in Biochemistry from UCLA.